logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Renal Cell Carcinoma

    FiltersReset Filters
    12 results

    • afinitor

      (everolimus)
      Novartis Pharmaceuticals Corporation
      Usage: AFINITOR is indicated for: advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women; progressive neuroendocrine tumors (PNET and non-functional GI/lung type); advanced renal cell carcinoma (RCC); TSC-associated renal angiomyolipoma; TSC-associated subependymal giant cell astrocytoma (SEGA); and partial-onset seizures related to TSC.

    • fotivda

      (Tivozanib)
      AVEO Pharmaceuticals, Inc.
      Usage: FOTIVDA is indicated for treating adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after two or more prior systemic therapies.

    • inlyta

      (axitinib)
      Pfizer Laboratories Div Pfizer Inc
      Usage: INLYTA is indicated for the first-line treatment of advanced renal cell carcinoma (RCC) in combination with avelumab or pembrolizumab. It is also indicated as a single agent for second-line treatment of advanced RCC following the failure of one prior systemic therapy.

    • inlyta

      (axitinib)
      U.S. Pharmaceuticals
      Usage: INLYTA is indicated for the first-line treatment of advanced renal cell carcinoma (RCC) in combination with avelumab or pembrolizumab. It is also indicated as a single agent for advanced RCC following the failure of one prior systemic therapy.

    • keytruda

      (pembrolizumab)
      Merck Sharp & Dohme LLC
      Usage: KEYTRUDA® is indicated for various cancers, including unresectable or metastatic melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and classical Hodgkin lymphoma, among others. It is utilized in different settings, such as first-line treatment, adjuvant therapy, and for those with advanced or refractory disease.

    • pazopanib

      (pazopanib hydrochloride)
      Novugen Pharma (USA) LLC.
      Usage: Pazopanib tablets are indicated for adults with advanced renal cell carcinoma and advanced soft tissue sarcoma after prior chemotherapy. Efficacy for adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated.

    • pazopanib

      (Pazopanib)
      SUN PHARMACEUTICAL INDUSTRIES, INC.
      Usage: Pazopanib tablets are indicated for the treatment of adults with advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy. Efficacy has not been established for adipocytic STS or gastrointestinal stromal tumors.

    • sorafenib

      (Sorafenib)
      Teva Pharmaceuticals Inc
      Usage: Sorafenib tablets are indicated for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and locally recurrent or metastatic, progressive differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.

    • sutent

      (Sunitinib malate)
      Pfizer Laboratories Div Pfizer Inc
      Usage: SUTENT is indicated for treating adult patients with gastrointestinal stromal tumors after imatinib progression or intolerance, advanced renal cell carcinoma, adjuvant treatment of high-risk recurrent renal cell carcinoma post-nephrectomy, and progressive well-differentiated pancreatic neuroendocrine tumors in advanced or metastatic stages.

    • temsirolimus

      (Temsirolimus Injection)
      Almaject, Inc.
      Usage: Temsirolimus injection is indicated for the treatment of advanced renal cell carcinoma.